When to Stop Allergy Shots: Signs You've Completed the Course

You are likely ready to stop allergy shots when three clinical criteria are met: you have experienced at least one full allergen season with minimal symptoms and minimal rescue medication use; your antihistamine and nasal steroid use has decreased significantly compared to your pre-immunotherapy baseline; and your quality of life — sleep, work or school performance, outdoor activities — has meaningfully improved. Your allergist will formally assess these criteria typically at the 3-5 year maintenance mark, ideally after your peak allergen season has passed so the seasonal assessment is complete. Objective immune markers such as reduced skin prick test wheal size, declining specific IgE, and rising IgG4 blocking antibodies can supplement symptom-based assessment. Ultimately, the stopping decision is a shared one between you and your allergist — do not stop independently without a formal evaluation.

Stopping allergy shots prematurely — typically defined as before completing 3 years of maintenance — significantly increases the likelihood of symptom relapse. Research by Eng et al. (Clinical and Experimental Allergy, 2006) showed that patients who complete a full 3-5 year course have substantially better long-term outcomes than those who discontinue at 1-2 years. The immune changes that produce durable tolerance — regulatory T-cell induction, IgG4 blocking antibody levels, downregulation of mast cell reactivity — require sustained antigen exposure over the maintenance phase to consolidate. Stopping during early maintenance means these changes have not been fully established. If you stop early, monitor symptoms carefully in the subsequent allergen season and discuss with your allergist whether retreatment is warranted if symptoms return significantly. Some partial benefit from incomplete treatment is retained, but durable protection is substantially lower.

No — the standard clinical protocol is to simply stop monthly maintenance injections after the agreed-upon duration without a dose taper. AAAAI practice parameters do not recommend tapering the dose before discontinuation. This differs from the approach for some other medications (like corticosteroids) where gradual taper is necessary. The immunological rationale: the immune tolerance achieved through immunotherapy does not depend on continued allergen exposure in the same dose-dependent way that some pharmacological effects do. Once tolerance has been established through the full maintenance course, abrupt stopping does not trigger a 'withdrawal' effect. Your allergist may schedule a final maintenance injection and then set follow-up monitoring appointments rather than scheduling any additional dose-reduction visits. If you have concerns about stopping without a taper, discuss this specifically with your allergist — some may use a modest reduction schedule as a clinical preference even though it is not evidence-required.

Benefits from a completed allergy shot course typically persist for 3 to 7 years post-stopping for most patients, though individual variation is significant. Durham et al. (NEJM, 1999) demonstrated lasting benefit at the 3-year post-treatment mark for grass pollen immunotherapy. The PAT study (Jacobsen et al., Allergy, 2007) showed disease-modifying effects — including asthma prevention and reduced new sensitizations in children — persisting beyond 7 years after a 3-year course. The underlying mechanism: IgG4 blocking antibodies and regulatory T-cell populations induced during treatment can be maintained by ongoing natural allergen exposure after treatment stops, creating a self-sustaining tolerance in some patients. Factors associated with longer post-treatment benefit include completing a full 3-5 year course, achieving good symptom control during treatment, and having a less complex multi-allergen sensitization profile.

Signs that your allergy shots may not be achieving their therapeutic goal include: returning or worsening symptoms during allergen seasons after initially improving, increased reliance on rescue medications compared to earlier in the treatment course, and no meaningful change in your quality of life after 12-18 months of maintenance. It is important to distinguish between 'shots stopped working' and 'new allergen sensitization' — sometimes patients develop IgE reactivity to a new allergen not included in their original extract formula, causing symptoms despite adequate treatment of the original triggers. Re-testing can clarify this. If you believe your shots are not working, discuss with your allergist before stopping — dose adjustment, extract reformulation, or a modified protocol may be more appropriate than discontinuation. True treatment failure (minimal response after 12+ months of maintenance) affects a minority of patients and warrants allergist re-evaluation of the diagnosis and extract composition.

Yes — restarting a second allergy shot course after symptom recurrence is a recognized clinical option. Approximately 10-25% of patients experience some degree of symptom recurrence within 3-5 years of completing their first course, and a second course is generally effective. The retreatment process starts the same way as the initial treatment: your allergist will reassess your current allergen sensitization profile (which may have changed, as new sensitivities can develop), review symptom severity and quality of life impact, and determine whether pharmacotherapy is currently adequate. If retreatment is warranted, the build-up and maintenance protocol is similar to the first course. No specific waiting period between courses is required, though most allergists prefer to observe at least 1-2 seasons of recurrent symptoms to confirm that retreatment is genuinely needed. Patients who completed a full first course often respond at least as well to a second course.